TY  - JOUR
A1  - Herrmann, Ken
A1  - Buck, Andreas K.
A1  - Schuster, Tibor
A1  - Abbrederis, Kathrin
A1  - Blümel, Christina
A1  - Santi, Ivan
A1  - Rudelius, Martina
A1  - Wester, Hans-Jürgen
A1  - Peschel, Christian
A1  - Schwaiger, Markus
A1  - Dechow, Tobias
A1  - Keller, Ulrich
T1  - Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
JF  - Oncotarget
N2  - Despite improved survival in the Rituximab (R) era, a considerable number of patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of residual viable tumor very early during treatment but is compromised by non-specific tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine (FLT) as surrogate marker of tumor proliferation may overcome this limitation. We present results of a prospective clinical study testing FLT-PET as superior and early predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive FLT-PET imaging was readily implemented into the diagnostic work-up. Our data demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax one week after chemotherapy was significantly higher in patients achieving complete response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional hazard analyses showed a significant monotonous decrease of mortality risk with increasing change in SUV. Consistent with these results, early FLT-PET response showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-PET in the course of R-CHOP chemotherapy is feasible and enables identification of patients at risk for treatment failure.
KW  - [18F]Fluorodeoxythymidine
KW  - FLT-PET
KW  - positron emission tomography
KW  - DLBCL
KW  - lymphoma
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-120659
SN  - 1949-2553
VL  - 5
IS  - 12
ER  - 
TY  - JOUR
A1  - Patel, Suketu
A1  - Murphy, Derek
A1  - Haralmbieva, Eugenia
A1  - Abdulla, Zainalabideen A.
A1  - Wong, Kah Keng
A1  - Chen, Hong
A1  - Gould, Edith
A1  - Roncador, Giovanna
A1  - Hatton, Chris S. R.
A1  - Anderson, Amanda P.
A1  - Banham, Alison H.
A1  - Pulford, Karen
T1  - Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas
JF  - Biomarker Insights
N2  - FAS-associated protein with death domain (FADD) is a major adaptor protein involved in extrinsic apoptosis, embryogenesis, and lymphocyte homeostasis. Although abnormalities of the FADD/death receptor apoptotic pathways have been established in tumorigenesis, fewer studies have analyzed the expression and role of phosphorylated FADD (pFADD). Our identification of FADD as a lymphoma-associated autoantigen in T-cell lymphoma patients raises the possibility that pFADD, with its correlation with cell cycle, may possess role(s) in human T-cell lymphoma development. This immunohistochemical study investigated pFADD protein expression in a range of normal tissues and lymphomas, particularly T-cell lymphomas that require improved therapies. Whereas pFADD was expressed only in scattered normal T cells, it was detected at high levels in T-cell lymphomas (eg, 84% anaplastic large cell lymphoma and 65% peripheral T cell lymphomas, not otherwise specified). The increased expression of pFADD supports further study of its clinical relevance and role in lymphomagenesis, highlighting phosphorylation of FADD as a potential therapeutic target.
KW  - autoantigen
KW  - lymphoma
KW  - pFADD
KW  - PTCL
KW  - FADD
KW  - ALCL
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-121403
SN  - 1177-2719
VL  - 9
ER  -